UTRN as a potential biomarker in breast cancer: a comprehensive bioinformatics and in vitro study

被引：1

作者：

Li H. ^{[1
]}

Zhang W. ^{[1
]}

Liu Y. ^{[1
]}

Cai Z. ^{[1
]}

Lan A. ^{[1
]}

Shu D. ^{[1
]}

Shen M. ^{[1
]}

Li K. ^{[1
]}

Pu D. ^{[1
]}

Tan W. ^{[1
]}

Liu S. ^{[1
]}

Peng Y. ^{[1
]}

机构：

[1] Department of Breast and Thyroid Surgery, the First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuzhong District, Chongqing

来源：

Scientific Reports | / 14卷 / 1期

关键词：

Breast cancer; CIBERSORT; ESTIMATE; Prognosis; Tumor microenvironment; UTRN;

D O I：

10.1038/s41598-024-58124-5

中图分类号：

学科分类号：

摘要：

Utrophin (UTRN), known as a tumor suppressor, potentially regulates tumor development and the immune microenvironment. However, its impact on breast cancer’s development and treatment remains unstudied. We conducted a thorough examination of UTRN using both bioinformatic and in vitro experiments in this study. We discovered UTRN expression decreased in breast cancer compared to standard samples. High UTRN expression correlated with better prognosis. Drug sensitivity tests and RT-qPCR assays revealed UTRN’s pivotal role in tamoxifen resistance. Furthermore, the Kruskal–Wallis rank test indicated UTRN’s potential as a valuable diagnostic biomarker for breast cancer and its utility in detecting T stage of breast cancer. Additionally, our results demonstrated UTRN’s close association with immune cells, inhibitors, stimulators, receptors, and chemokines in breast cancer (BRCA). This research provides a novel perspective on UTRN’s role in breast cancer’s prognostic and therapeutic value. Low UTRN expression may contribute to tamoxifen resistance and a poor prognosis. Specifically, UTRN can improve clinical decision-making and raise the diagnosis accuracy of breast cancer. © The Author(s) 2024.

引用

共 34 条

[1] Sung H., Et al., Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin, 71, pp. 209-249, (2021)
[2] Katzenellenbogen J.A., Mayne C.G., Katzenellenbogen B.S., Greene G.L., Chandarlapaty S., Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance, Nat. Rev. Cancer, 18, pp. 377-388, (2018)
[3] Binkhorst L., van Gelder T., Mathijssen R.H., Individualization of tamoxifen treatment for breast carcinoma, Clin. Pharmacol. Ther, 92, pp. 431-433, (2012)
[4] Musgrove E.A., Sutherland R.L., Biological determinants of endocrine resistance in breast cancer, Nat. Rev. Cancer, 9, pp. 631-643, (2009)
[5] Howlader N., Et al., US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status, J. Natl. Cancer Inst, (2014)
[6] Szostakowska M., Trebinska-Stryjewska A., Grzybowska E.A., Fabisiewicz A., Resistance to endocrine therapy in breast cancer: Molecular mechanisms and future goals, Breast Cancer Res. Treat, 173, pp. 489-497, (2019)
[7] Yao J., Deng K., Huang J., Zeng R., Zuo J., Progress in the understanding of the mechanism of tamoxifen resistance in breast cancer, Front. Pharmacol, 11, (2020)
[8] Kalluri R., The biology and function of fibroblasts in cancer, Nat. Rev. Cancer, 16, pp. 582-598, (2016)
[9] Hanahan D., Coussens L.M., Accessories to the crime: Functions of cells recruited to the tumor microenvironment, Cancer cell, 21, pp. 309-322, (2012)
[10] Li D., Et al., Tumor-associated macrophages secrete CC-chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer, Cancer Sci, 111, pp. 47-58, (2020)

← 1 2 3 4 →